(XBI) SPDR S&P Biotech - Ratings and Ratios
Stocks, Biotech, Small-Cap, Mid-Cap, Equal-Weight
Dividends
| Dividend Yield | 0.03% |
| Yield on Cost 5y | 0.03% |
| Yield CAGR 5y | -17.13% |
| Payout Consistency | 44.8% |
| Payout Ratio | - |
| Risk via 10d forecast | |
|---|---|
| Volatility | 26.2% |
| Value at Risk 5%th | 44.2% |
| Relative Tail Risk | 2.42% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 0.73 |
| Alpha | 8.44 |
| CAGR/Max DD | 0.45 |
| Character TTM | |
|---|---|
| Hurst Exponent | 0.492 |
| Beta | 0.909 |
| Beta Downside | 0.848 |
| Drawdowns 3y | |
|---|---|
| Max DD | 32.99% |
| Mean DD | 10.81% |
| Median DD | 10.15% |
Description: XBI SPDR S&P Biotech November 06, 2025
The SPDR S&P Biotech ETF (ticker XBI) aims to replicate the S&P Biotechnology Select Industry Index by using a sampling approach, allocating at least 80 % of its assets to the index’s constituents. The index captures the biotech segment of the broader S&P Total Market Index, providing exposure to a diversified basket of U.S. biotechnology firms.
Key quantitative details (as of the latest filing) include an expense ratio of roughly 0.35 %, about 140 holdings with a median market-cap near $2 billion, and a weighted average dividend yield close to 0 % (reflecting the sector’s growth focus). Recent performance has been driven by a surge in FDA approvals-biotech companies saw a 12 % YoY increase in new drug clearances in 2024-and robust R&D spending, which grew at an annualized 8 % rate, supporting pipeline expansion.
Macro-level drivers such as U.S. healthcare policy stability, the pace of gene-therapy commercialization, and the availability of venture capital continue to shape sector risk-reward dynamics.
For a deeper dive into XBI’s valuation metrics and risk profile, you might explore the analysis on ValueRay.
What is the price of XBI shares?
Over the past week, the price has changed by -0.83%, over one month by +10.90%, over three months by +30.13% and over the past year by +24.77%.
Is XBI a buy, sell or hold?
What are the forecasts/targets for the XBI price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 131.7 | 8.1% |
XBI Fundamental Data Overview November 29, 2025
Beta = 1.26
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 7.30b USD (7.30b + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 7.30b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 7.30b / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 9.37% (E(7.30b)/V(7.30b) * Re(9.37%) + (debt-free company))
Discount Rate = 9.37% (= CAPM, Blume Beta Adj.)
Fair Price DCF = unknown (Cash Flow 0.0)
Additional Sources for XBI ETF
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle